1.Expert consensus on the application of nasal cavity filling substances in nasal surgery patients(2025, Shanghai).
Keqing ZHAO ; Shaoqing YU ; Hongquan WEI ; Chenjie YU ; Guangke WANG ; Shijie QIU ; Yanjun WANG ; Hongtao ZHEN ; Yucheng YANG ; Yurong GU ; Tao GUO ; Feng LIU ; Meiping LU ; Bin SUN ; Yanli YANG ; Yuzhu WAN ; Cuida MENG ; Yanan SUN ; Yi ZHAO ; Qun LI ; An LI ; Luo BA ; Linli TIAN ; Guodong YU ; Xin FENG ; Wen LIU ; Yongtuan LI ; Jian WU ; De HUAI ; Dongsheng GU ; Hanqiang LU ; Xinyi SHI ; Huiping YE ; Yan JIANG ; Weitian ZHANG ; Yu XU ; Zhenxiao HUANG ; Huabin LI
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2025;39(4):285-291
This consensus will introduce the characteristics of fillers used in the surgical cavities of domestic nasal surgery patients based on relevant literature and expert opinions. It will also provide recommendations for the selection of cavity fillers for different nasal diseases, with chronic sinusitis as a representative example.
Humans
;
Nasal Cavity/surgery*
;
Nasal Surgical Procedures
;
China
;
Consensus
;
Sinusitis/surgery*
;
Dermal Fillers
2.Analyses of the influence of diabetes-related deaths on the probability of premature mortality and life expectancy in Minhang District, Shanghai from 2004 to 2023
Shuili XUAN ; Jingyi NI ; Jiaqi GUO ; Wei LIU ; Lijing CHEN ; Yibin ZHOU ; Linli CHEN ; Huilin XU
Shanghai Journal of Preventive Medicine 2025;37(9):752-758
ObjectiveTo analyze the impact of diabetes-related deaths on the probability of premature mortality and life expectancy in Minhang District of Shanghai from 2004 to 2023, and to provide reference data for the optimization of targeted prevention and control strategies. MethodsAll death cases involving diabetes among the registered residents of Minhang District from 2004 to 2023 were collected. The probability of premature mortality and life expectancy was computed using the abridged life table method. The average annual percent change (AAPC) was calculated with Joinpoint 4.9.0.0. The Arriaga decomposition method was employed for statistical analyses of the influence of cause-specific and age-specific mortality related to diabetes on life expectancy. ResultsThe total number of diabetes-related mortality, crude mortality, and standardized mortality for both males and females in Minhang District from 2004 to 2023 exhibited an increasing trend (P<0.001). The primary causes of death among diabetes-related cases were cardiovascular disease (37.68%), diabetes mellitus (31.95%), and malignant tumor (17.80%). From 2004 to 2023, probability of premature mortality to diabetes-related diseases demonstrated a rising trend (P<0.001), contrasting with the declining trend observed in the overall population (P=0.001). Males showed a significant upward trajectory (P<0.001), while females displayed a stable pattern. Among the diseases exerting considerable influence, cardiovascular disease and malignant tumor revealed a marked increase over time (P<0.001), whereas diabetes mellitus maintained a stable trend; both factors negatively impacted the reduction in probability of premature mortality. From 2004 to 2023, diabetes-related mortality reduced life expectancy among residents by an average of 1.22 years (-49.89%), indicating a negative impact; the reduction was 1.41 years in males and 0.90 years in females. The age groups exhibiting greater negative contributions differed by genders, namely males aged 50‒54 years and females aged 70‒74 years. Cardiovascular disease, diabetes mellitus, and malignant tumor contributed significantly to this decline (-0.46 years, -0.42 years, -0.20 years, respectively), with male experiencing higher negative contributions than females. ConclusionIn Minhang District, the rising mortality associated with diabetes-related diseases negatively impact both the reduction of the probability of premature mortality and the increase in life expectancy. This trend is primarily attributed to the rapid escalation of mortality and younger age demographic of male residents, which warrants significant attention. It is recommended that, based on the enhancement of case management, efforts should be directed towards the targeted prevention and control of risk factors and high-risk populations.
3.Status quo and countermeasures of job mobility among clinical research coordinator/clinical research associate in Chongqing
Liya CAO ; Yongchuan CHEN ; Wei GUO ; Linli XIE
China Pharmacy 2022;33(3):275-279
OBJECTIVE To investigate the job mo bility of cl inical research coordinators (CRCs) and clinical research associates(CRAs)in Chongqing ,and to explore the feasible methods to improve the job stability of CRCs and CRAs. METHODS Questionnaire survey was conducted to investigate the job mobility of 200 CRCs and CRAs working in 22 drug clinical trial institutions of Chongqing. The contents included basic information ,job mobility ,and reasons for mobility. RESULTS & CONCLUSIONS Totally 178 valid questionnaires were recovered ,with an efficient recovery rate of 89.00%,of which 110 were recovered from CRCs and 68 were recovered from CRAs. Among the surveyed CRCs and CRAs ,the age distribution was mainly 20-30 years old ,accounting for 87.27% and 82.35% of the respective population respectively. The overall educational degree of CRAs were slightly higher than those of CRCs. The majors and previous work experience were mainly related to medicine ;the proportion of other non-medicine-related professions who switched to CRCs was higher than that of CRAs. Totally 88.18% had CRC working experience within 3 years;after having 1-<3 years of work experience ,50.00% had worked in 2 or more work units. Totally 64.70% had CRA working experience within 3 years;after having 1-<3 years of work experience ,70.37% had worked in 2 or more work units. CRCs handled 5.38 items of clinical trials and completed 1.22 items on average ;CRAs handled 7.47 items and completes 2.04 items on average. Main reasons of CRCs and CRAs for job-hopping included low salary below expectations,few promotion opportunities ,and too much workload ,accounting for 83.64%/80.88%,45.45%/39.71%,31.82%/ 26.47%,respectively. As an important part of clinical trials ,CRCs and CRAs had high job mobility. It is suggested to establish a unified industry standard ,standardize the management rights and responsibilities of CRCs and CRAs ,optimize the working mode of CRCs and CRAs ,and improve professional identity and sense of belonging ,so as to improve the job stability of relevant
4.Influence of female age on the fresh cycle live birth rate of different controlled ovarian hyperstimulation protocols in poor ovarian response patients
Fei LI ; Tian YE ; Huijuan KONG ; Jing LI ; Linli HU ; Hongyi YANG ; Yihong GUO ; Gang LI
Chinese Journal of Obstetrics and Gynecology 2021;56(7):482-488
Objective:To investigate the influence of age on the fresh cycle live birth rate in patients with poor ovarian response in different controlled ovarian hyperstimulation groups.Methods:The clinical data of 3 342 patients in The First Affiliated Hospital of Zhengzhou University from February 2014 to November 2018 were retrospectively collected, including early-follicular phase long-acting gonadotropin-releasing hormone (GnRH) agonist long protocol group (1 375 cases), mid-luteal phase short-acting GnRH agonist long protocol group (1 161 cases) and GnRH antagonist protocol group (806 cases); each group was divided into 4 subgroups according to age: ≤30 years, 31-35 years, 36-40 years and >40 years, the pregnancy outcomes in each age subgroup were analyzed under different controlled ovarian hyperstimulation protocols.Results:In early-follicular phase long-acting GnRH agonist long protocol group, the final live birth rates of each age subgroup were 39.4% (228/579), 36.1% (135/374), 16.6% (48/290) and 3.0% (4/132); in mid-luteal phase short-acting GnRH agonist long protocol group, live birth rates of each age subgroup were 32.1% (99/308), 20.8% (55/264), 13.0% (45/346) and 7.0% (17/243); in GnRH antagonist protocol group, live birth rates of each age subgroup were 22.8% (26/114), 16.3% (25/153), 11.2% (31/278), and 3.8% (10/261); the live birth rate of each group decreased significantly with the increase of age (all P<0.01). When the age≤35 years old, the fresh cycle live birth rate of the early-follicular phase long-acting GnRH agonist long protocol group was significantly better than those of the other two groups (all P<0.01). The multivariate logistic regression analysis of age and live birth rate of the three controlled ovarian hyperstimulation groups showed age was the independent influence factor ( OR=0.898, 95% CI: 0.873-0.916, P<0.01; OR=0.926, 95% CI: 0.890-0.996, P<0.01; OR=0.901, 95% CI: 0.863-0.960, P<0.01). Conclusions:Age is an independent influencing factor for the prediction of fresh cycle live birth rate in low ovarian response patients. No matter which controlled ovarian hyperstimulation protocol is adopted, the final live birth rate decreases significantly with the increase of women′s age. In addition, the early-follicular phase long-acting GnRH agonist long protocol has the highest fresh cycle live birth rate among all controlled ovarian hyperstimulation groups.
5.CT Quantitative Analysis and Its Relationship with Clinical Features for Assessing the Severity of Patients with COVID-19
Dong SUN ; Xiang LI ; Dajing GUO ; Lan WU ; Ting CHEN ; Zheng FANG ; Linli CHEN ; Wenbing ZENG ; Ran YANG
Korean Journal of Radiology 2020;21(7):859-868
Objective:
To investigate the value of initial CT quantitative analysis of ground-glass opacity (GGO), consolidation, and total lesion volume and its relationship with clinical features for assessing the severity of coronavirus disease 2019 (COVID-19).
Materials and Methods:
A total of 84 patients with COVID-19 were retrospectively reviewed from January 23, 2020 to February 19, 2020. Patients were divided into two groups: severe group (n = 23) and non-severe group (n = 61). Clinical symptoms, laboratory data, and CT findings on admission were analyzed. CT quantitative parameters, including GGO, consolidation, total lesion score, percentage GGO, and percentage consolidation (both relative to total lesion volume) were calculated. Relationships between the CT findings and laboratory data were estimated. Finally, a discrimination model was established to assess the severity of COVID-19.
Results:
Patients in the severe group had higher baseline neutrophil percentage, increased high-sensitivity C-reactive protein (hs-CRP) and procalcitonin levels, and lower baseline lymphocyte count and lymphocyte percentage (p < 0.001). The severe group also had higher GGO score (p < 0.001), consolidation score (p < 0.001), total lesion score (p < 0.001), and percentage consolidation (p = 0.002), but had a lower percentage GGO (p = 0.008). These CT quantitative parameters were significantly correlated with laboratory inflammatory marker levels, including neutrophil percentage, lymphocyte count, lymphocyte percentage, hs-CRP level, and procalcitonin level (p < 0.05). The total lesion score demonstrated the best performance when the data cut-off was 8.2%. Furthermore, the area under the curve, sensitivity, and specificity were 93.8% (confidence interval [CI]: 86.8–100%), 91.3% (CI: 69.6–100%), and 91.8% (CI: 23.0–98.4%), respectively.
Conclusion
CT quantitative parameters showed strong correlations with laboratory inflammatory markers, suggesting that CT quantitative analysis might be an effective and important method for assessing the severity of COVID-19, and may provide additional guidance for planning clinical treatment strategies.
6.Influence and Reflections on the Work of Drug Clinical Trial Institutions in China after Joining in ICH
Wei GUO ; Linli XIE ; Liya CAO ; Yongchuan CHEN
China Pharmacy 2019;30(11):1445-1448
OBJECTIVE: To summarize the problems and countermeasures which the construction of drug clinical trial institutions face after China Food and Drug Administration (CFDA) join in ICH, and its effects on clinical study management in China. METHODS: Combined with the experience on Good Clinical Practice (GCP) in our hospital during recent years, reviewing related content of ICH-GCP, the differences between China’s GCP (CFDA-GCP) and ICH-GCP, the problems faced by drug clinical trial institutions after joining in ICH, and the thinking of China’s clinical research were discussed. RESULTS & CONCLUSIONS: There were differences between CFDA-GCP and ICH-GCP in the management concept of clinical drug trials, the structure and function of ethical committees, the protection of the rights and interests of subjects, the choice of researchers and research institutions, management requirements of experimental drugs and the management of documents and data. After joining in ICH, the current organization and management structure, system and standard operating procedures, ethics committee, GCP training and continuing education, professional quality control system, experimental drug management, data management and information system construction and upgrading, clinical research coordinator management and other aspects of the drug clinical trial institutions were far from the requirements of ICH. The standardization of drug clinical trial institutions in China can be further promoted by revising regulations and guidelines, formulating standard operating procedures in line with ICH-GCP, building standardized ethics committees, implementing GCP training and continuing education, improving quality control system and drug management in clinical trials, strengthening hardware and software construction and clinical coordinator management, etc. At the same time, problems such as fewer full-time personnel and weak implementation of the system can be improved by strengthening project management, improving the quality of employees and building normal cross-regional cooperation.
7.Talking about the Key Points and Notices of Drug Management in Clinical Trials
Jiangchuan XIE ; Wei GUO ; Linli XIE ; Minghong LI ; Xinmei PAN ; Liya CAO ; Yongchuan CHEN
China Pharmacy 2019;30(21):2894-2898
OBJECTIVE: To provide references for improving the standard operating procedures of drug management in clinical trials and drug management in clinical trials. METHODS: According to Good Clinical Practice (GCP), Data On-site Verification Points of Drugs Clinical Trial, Qualification Examination Rules of Drug Clinical Trial Institution, based on the quality control project carried out in our hospital since July 2016, the matters needing attention in the non-standard operation and key process of drug management in clinical trial were summarized, and the improvement measures were discussed. RESULTS & CONCLUSIONS: Non-standard drug management is a high-incidence link of non-standard operation in the trial process. Among them, the acceptance, distribution and use of drugs are the three links with the highest incidence of non-standard operation of drug management in the trial process. Therefore, when formulating the relevant management system, each institution should pay attention to it according to its own situation; such as, when accepting drugs in clinical trials, attention should be paid to checking the intact degree of drug packaging; drugs transported in cold chain should also be checked for temperature records and rejected in case of over-temperature; the copies of the waybill should be kept in file with the original to avoid fading of the thermosensitive paper; whether the relevant characteristics of the control drugs and placebos meet the requirements. Institutions can standardize the key links of drug management in the trial process, the time of project establishment, project start-up, quality control and supervision, formulate and constantly improve the relevant drug management system and standard operating procedures (SOP). For example, when starting a project, attention should be paid to the participation of drug administrators in the training and signature of start-up meeting, whether the design of the form is complete, standardized and operable. It is necessary for clinical trial institutions to pay attention to the standardization and precision of drug management and the key links in clinical trials.
8.Application of the anxiety and depression scale of patients with nasal septum deviation.
Ran AN ; Linli TIAN ; Ming LIU ; Yanan SUN ; Yan ZHENG ; Rui ZHAO ; Yan GUO
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2016;30(1):35-38
OBJECTIVE:
To evaluate the anxiety and depression status of patients with nasal septum deviation before and after surgery, and explore the relationship between anxiety and depression and nasal symptoms.
METHOD:
By means of visual analogue scale (VAS) as the evaluation index of quality of life, self-rating anxiety scale (SAS) and self-rating depression scale (SDS) were used to analyze statuses before and after surgery. The 98 patients with nasal septum deviation were collected.
RESULT:
The preoperative SAS/SDS scores of the nasal septum deviation patients were higher than those of the national standards. The level of anxiety and depression were lower than the national norm after treatment. The patients of the normal and moderate SAS/SDS scores felt better after surgery. The patients of the severe SAS/SDS scores felt the symptoms improve poor.
CONCLUSION
Doctors should pay attention to the application of the SAS/SDS in patients of nasal septum deviation. Surgeon should actively communicate with severe patients in psychological problems, and strictly control the surgical indication of such patients.
Anxiety
;
complications
;
Depression
;
complications
;
Humans
;
Nasal Septum
;
abnormalities
;
Psychiatric Status Rating Scales
;
Quality of Life
;
Self Report
9.Clinical observation of iron removal treatment with week-therapy of chronic iron overload
Ting WANG ; Yanjun WANG ; Linli PAN ; Jie WU ; Lei ZHANG ; Yini GUO
Journal of Leukemia & Lymphoma 2013;22(8):491-493
Objective To explore the clinical application and curative effect of iron removal treatment with week-therapy in chronic iron overload related to blood transfusion.Methods Twenty patients who were diagnosed as chronic iron overload were retrospectively studied.The amelioration of liver and pancreatic fanctions in patients with chronic iron overload treated with week-therapy of iron chelating agent through intravenous drip.Results The changes in the level of serum ferritin [2693.7±709.9) μg/L] were not significant after treatment at six months,hut the cilinical symptoms were relieved obviously.The levels of serum ferritin in patients after the treatment at twelve months were significantly different from the level before treated [(2083.7±714.4) μg/L vs (2771.5±725.2) μg/L,t =3.35,P < 0.01],and the decreases were significant in sixteen patients.The liver functions in seven patients were improved and pancreatic functions were better in five patients.Conclusion The study suggests that iron removal treatment with week-therapy is effective for chronic iron overload,and improves the functions of damaged organs.
10.Reconstruction of soft tissue defect of the foot dorsum with trimmed latissimus dorsi free muscle flap with skin grafting
Yan HAN ; Baoqiang SONG ; Wei ZENG ; Shuzhong GUO ; Yong PAN ; Wenseng XIA ; Hongyan YANG ; Linli GUO ; Dan LI
Chinese Journal of Microsurgery 2012;35(4):276-278,后插2
Objective To discuss the clinical application of using trimmed latissimus dorsi free muscle flap together with skin grafting to resurface soft tissue defects on the dorsum of the foot. Methods From June 2005 to October 2011,eleven patients (8 males and 3 females,aged from 4-46 years) with large soft tissue defects of the foot dorsum were treated in our department. The size of the defects after debridement ranged from 5.0 cm × 6.0 cm-8.0 cm × 12.0 cm,all with exposed tendons or bones.Trimmed free latissimus dorsi muscular flap with split thickness skin grafting was used for reconstruction for all the 11 patients. Results All the flaps survived with no complications after surgery.During 3-10 months' follow-up,the appearance and walking function were satisfying, no further debulking procedures were needed. Conclusion Trimmed latissimus dorsi free flap with skin grafting is a good option for dorsal defect reconstruction.

Result Analysis
Print
Save
E-mail